New Drug Daraxonrasib Doubles Survival Time for Metastatic Pancreatic Cancer Patients
A targeted pill called daraxonrasib helped patients with metastatic pancreatic cancer live nearly twice as long as those receiving standard chemotherapy, according to trial results published in April 2026. Patients on the drug had a median survival of 13.2 months compared to 6.7 months for chemotherapy.
A targeted pill called daraxonrasib has shown strong results in a clinical trial for metastatic pancreatic cancer, one of the deadliest forms of the disease.
Patients who received daraxonrasib had a median survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The results were published in April 2026 and represent a significant step forward for a cancer that has historically been difficult to treat.
Pancreatic cancer is often diagnosed at a late stage, when surgery is no longer an option. Most patients with metastatic disease survive less than a year on current treatments. The daraxonrasib results suggest a new option may be on the horizon.
The drug works by targeting a specific molecular pathway that drives tumor growth in a subset of pancreatic cancer patients. Researchers said identifying which patients are most likely to benefit will be an important next step.
Adolescent and young adult cancer survivors were also highlighted in separate research this month, with studies showing they face an increased risk of developing future cancers. Doctors are being urged to provide long-term follow-up care for this population.
New research also found that new-onset anemia is linked to a higher cancer risk and mortality, suggesting that unexplained anemia should prompt further investigation for underlying malignancy.
The daraxonrasib trial results are expected to support applications for regulatory approval in the United States and Europe.
